Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 1—January 2020
Research Letter

Hantavirus Pulmonary Syndrome in Traveler Returning from Nepal to Spain

Elena Sulleiro1, Maria Luisa Aznar1, Núria Serre-Delcor, Fernando Salvador, Adrian Sanchez-Montalvá, Mateu Espasa, Daniel Molina, Fernando de Ory, M. Paz Sanchez-Seco, Israel Molina, Candido Diaz-Lagares, Miguel J. Martinez, Tomàs Pumarola, and Inés OliveiraComments to Author 
Author affiliations: Vall d’Hebrón University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain (E. Sulleiro, M.L. Aznar, N. Serre-Delcor, F. Salvador, A. Sanchez-Montalvá, M. Espasa, D. Molina, I. Molina, C. Diaz-Lagares, T. Pumarola, I. Oliveira); Instituto de Salud Carlos III, Majadahonda, Spain (F. de Ory, M.P. Sanchez-Seco); Hospital Clínic, Barcelona (M.J. Martinez)

Main Article

Table

Clinical and laboratory findings over time of a patient with hantavirus pulmonary syndrome after travel, Spain*

Findings Acute phase, day 2 ICU admission, day 6 ICU discharge, day 12 Follow-up, day 22 Follow-up, day 82
Clinical
Fever, myalgia, headache, vomiting, and diarrhea
Acute noncardiac pulmonary edema and hypotension; pleural effusions and respiratory failure
Eupneic, resolution of the pulmonary edema
Mild dyspnea general condition with fatigue
Completely recovered
Hematalogic
Leukocytes 4.38 × 109 cells/L; platelets 125 × 109/L
Leukocytes 6.17 × 109 cells/L; platelets 92 × 109/L
Leukocytes 7.00 × 109 cells/L; platelets 306 × 109/L
Leukocytes 4.91 × 109 cells/L; platelets 205 × 109/L
Leukocytes 5.82 × 109 cells/L; platelets 208 × 109/L
Biochemical
AST 81 IU/L; ALT 127 IU/L; ALP 142 IU/L; GGT 128 IU/L; creatinine 1.02 g/dL; urea 37 mg/dL; Na+ 140 mmol/L; K+ 4.24 mmol/L; cholesterol 113 mg/dL; triglycerides 78 mg/dL; CRP 10.33
AST 448 IU/L; ALT 424 IU/L; ALP 151 IU/L; GGT 150 IU/L; cardiac biomarkers (troponin and natriuretic peptide) normal; creatinine 0.86 mg/dL; urea 53 mg/dL; Na+ 135.6 mmol/L; K+ 4.39 mmol/L; LDH 830 UI/L; CRP 14.58
AST 117 IU/L; ALT 205 IU/L; Creatinine 0.56 mg/dL; Urea 28 mg/dL; Na+ 141.8 mmol/L; K+ 4.38 mmol/L; cholesterol 121 mg/dL; triglycerides 218 mg/dL; CRP 2.81
AST 46 IU/L; ALT 106 IU/L; ALP 176 IU/L; GGT 143 IU/L; creatinine 0.71 mg/dL; Urea 30 mg/dL; Na+ 139.5 mmol/L; K+ 4.58 mmol/L
AST 24 IU/L; ALT 19 IU/L; GGT 12 IU/L; creatinine 0.95 mg/dL; urea 33 mg/dL; Na+ 140.2 mmol/L; K+ 4.78 mmol/L
Arterial blood gas analysis
NA
pH 7.36; PaCO2 32 mm Hg; PaO2 40 mm Hg; SaO2 85.5%; HCO3- 26.3 mm Hg
NA
NA
NA
Pleural effusion characteristics
NA
Glucose 114 mg/dL; proteins 2.1 g/dL; LDH 423 IU/L; cytology inflammatory process with lymphocyte predominance
NA
NA
NA
Hantavirus diagnosis IgG (ELISA) negative; IgG (IBT) negative; IgM (ELISA) negative; IgM (IBT) negative; PCR (serum + urine) negative NA IgG (ELISA) weak positive; IgG (IBT) positive, PUUV indeterminate, Dobrava Seoul, Hantaan, Sin Nombre and Andes negative; IgM (ELISA) indeterminate; IgM (IBT) negative; PCR (serum) negative; DENV IgG, IgM negative, PCR (serum) negative IgG (ELISA) positive; IgG (IBT) positive; PUUV indeterminate; Dobrava, Sin Nombre and Andes and negative Seoul and Hantaan; IgM (ELISA) positive; IgM (IBT) negative; PCR (serum) negative IgG (ELISA) indeterminate; IgG (IBT) indeterminate; PUUV, Dobrava, and Seoul negative Hantaan, Sin Nombre and Andes; IgM (ELISA) negative; IgM (IBT) negative; PCR (serum) negative

*Days are days after initial symptom onset. An expanded table including additional results is available (https://wwwnc.cdc.gov/EID/article/26/1/18-1685-T1.htm). ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; DENV, dengue virus; GGT, gamma-glutamyl transpeptidase; IBT, immunoblot; ICU, intensive care unit; LDH, lactate dehydrogenase; NA, not applicable; PUUV, Puumala virus.

Main Article

1These authors contributed equally to this article.

Page created: December 18, 2019
Page updated: December 18, 2019
Page reviewed: December 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external